Titan Pharmaceuticals, Inc

Celldex Therapeutics is a biopharmaceutical company that applies its Immunotherapy Platform to treat various diseases. Its immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. Celldex Therapeutics technology platform uses human monoclonal antibodies administered directly to patients to target dendritic cells and macrophages that are key cells in the immune system. Its APC Targeting Technology delivers an antigen that results in more efficient processing than a nontargeted antigen. The company develops various therapeutic human monoclonal antibody products. Its lead programs are for oncology targets. Celldex Therapeutics has two clinical programs under clinical evaluation for the therapy of cancer.

SIGA Technologies applies microbial genomics to the design and development of novel products that prevent and treat infectious diseases, as well as defend against biological warfare agents. With technology platforms in both vaccines and antibiotics, the company s platform technologies include a vaccine delivery system that activates the immune system at the body s mucosal surfaces in order to prevent infection at the earliest possible stage, a surface protein expression system for the cost-effective production of proteins, biothreat rapid response therapeutics that can be rapidly designed on demand for any biological pathogen and virus counterstrike capability technology that can be used to develop safe and effective antivirals by targeting the proteinases which are encoded within all viruses. SIGA Technologies is headquartered in New York.

MeiraGTx is a clinical-stage genetic medicine company based in New York that is dedicated to unlocking the potential of genetic therapies for both rare and prevalent diseases. The company employs pioneering technologies, including a unique riboswitch gene regulation platform, to achieve precision control of gene expression, which can transform the treatment landscape for various disorders. With a commitment to improving patient lives, MeiraGTx integrates advanced science and an extensive manufacturing ecosystem to provide tailored treatments. Their diverse clinical pipeline reflects the company's focus on addressing inherited and non-inherited diseases through innovative approaches to genetic medicine. Generated from the website